Skip to Content

Incyte Corp INCY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Maintaining Our $120 Incyte FVE Following Weak First Quarter; Rux Cream Launch a Key Catalyst

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

We're maintaining our $120 fair value estimate for Incyte following first-quarter results that were slightly below our expectations, reflecting continued COVID-19-related pressure on U.S. sales of hematology drug Jakafi. We think recovery in patient demand in March and management's decision to maintain prior full-year guidance for Jakafi sales bode well for growth for the remainder of the year, and we're only slightly lowering our own estimate for 2021 U.S. Jakafi sales from $2.2 billion to $2.1 billion. Sales of Jakafi in the U.S. grew 1% in the quarter to reach $466 million, as COVID-19-related stocking in the first quarter of last year and increased discounting this quarter were countered by demand growth. Incyte's total revenue grew 6%, driven by the launch of Pemazyre in cholangiocarcinoma as well as double-digit royalty growth from international sales of Jakavi (Novartis) and global sales of immunology drug Olumiant (Lilly). We think Incyte's differentiated therapy Jakafi as well as a growing portfolio in hematology and immunology continue to support a narrow moat.

Read Full Analysis

Company Profile

Business Description

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.

Contact
1801 Augustine Cut-Off
Wilmington, DE, 19803
T +1 302 498-6700
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 1,773

Related

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.